Company Secretary

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com Email: co.secretary@biocon.com BIO/SECL/TG/2026-27/68 September 25, 2026 To To The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol - BIOCON Subject: Company Statement Dear Sir/Madam, Please find enclosed Company Statement w.r.t. “Biocon Malaysia Receives MHRA Approval for New Drug Product Fill Finish Unit for Insulins”. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328 Encl: Company Statement NOTIFICATION TO STOCK EXCHANGE COMPANY STATEMENT Biocon Malaysia Receives MHRA Approval for New Drug Product Fill Finish Unit for Insulins Bengaluru, Karnataka, India, September 25, 2026 Biocon Limited (BSE code: 532523, NSE: BIOCON) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia. In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.